SABR + 177Lu-PSMA-617 + niraparib + abiraterone acetate

This is a multi-modal combination regimen for the treatment of **prostate cancer**, typically metastatic castration-resistant prostate cancer (mCRPC). - **SABR** (Stereotactic Ablative Body Radiotherapy) is a highly precise radiation therapy that delivers high doses of radiation to localized tumors. - **177Lu-PSMA-617** (Pluvicto) is a radiopharmaceutical agent that delivers beta radiation specifically to prostate cancer cells overexpressing Prostate-Specific Membrane Antigen (PSMA), thus selectively destroying cancer cells while limiting damage to healthy tissue[1][4][10]. - **Niraparib** is an oral poly (ADP-ribose) polymerase (PARP) inhibitor that leads to the accumulation of DNA damage in cancer cells, particularly those with BRCA mutations[2][5][8]. - **Abiraterone acetate** is an androgen biosynthesis inhibitor that blocks CYP17, thereby inhibiting androgen production (a driver of prostate cancer progression)[2][5][8]. Niraparib and abiraterone acetate are available as a fixed-dose combination tablet (Akeega) approved for BRCA-mutated prostate cancer, often administered with prednisone[2][8]. The combination aims to provide synergistic effects: tumor cytoreduction by SABR, targeted cytotoxicity by 177Lu-PSMA-617, genomic instability induction by niraparib, and hormonal pathway inhibition by abiraterone acetate.

Brand names

Akeega (for niraparib/abiraterone acetate combination)

Other names

SABR + lutetium-177 PSMA-617 + niraparib + abiraterone acetate